What is the recommended approach to evaluating and managing a patient presenting with prolonged bleeding?

Approach to Prolonged Bleeding

The initial approach to prolonged bleeding must immediately stratify severity: if the patient has bleeding at a critical site (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, or intramuscular with compartment syndrome), hemodynamic instability, or hemoglobin drop ≥2 g/dL requiring ≥2 units RBCs, this is major bleeding requiring immediate anticoagulant discontinuation, aggressive resuscitation, and consideration of reversal agents—whereas non-major bleeding can often be managed with local hemostatic measures alone. 1

Immediate Severity Assessment

Determine if ≥1 of the following applies:

• Bleeding at a critical site (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intramuscular with compartment syndrome)
• Hemodynamic instability (hypotension, tachycardia, altered mental status)
• Clinically overt bleeding with hemoglobin decrease ≥2 g/dL OR transfusion of ≥2 units RBCs

If YES → Major bleeding
If NO → Non-major bleeding 1

Management Algorithm for Major Bleeding

Critical Site or Life-Threatening Bleeding

Stop all anticoagulants and antiplatelet agents immediately 1

Initiate simultaneous interventions:

• Local therapy/manual compression at bleeding site
• Supportive care and volume resuscitation (crystalloids, blood products as needed)
• Assess and manage comorbidities contributing to bleeding (thrombocytopenia, uremia, liver disease)
• Consider surgical/procedural management of bleeding site—do not delay definitive hemostatic procedures waiting for reversal 2

For patients on anticoagulants:

• If on vitamin K antagonist (VKA): Give 5-10 mg IV vitamin K 1
• Measure anticoagulation level immediately (INR for VKAs, drug-specific assays for DOACs when available)
• For intracranial hemorrhage or hemorrhagic shock: Administer reversal agents WITHOUT waiting for laboratory results unless available within minutes 2

Reversal/hemostatic agents:

• VKAs: Prothrombin complex concentrates (PCCs) + vitamin K
• Dabigatran: Idarucizumab
• Apixaban/Rivaroxaban: Andexanet alfa or PCCs
• All major bleeding: Consider tranexamic acid per standard trauma/hemorrhage indications (same indications as non-anticoagulated patients) 2

The 2025 French guidelines 2 emphasize that reversal must not delay definitive hemostatic procedures (surgery, embolization, endoscopy). However, complete biological reversal improves procedural effectiveness and reduces mortality—high INR reduces endoscopy effectiveness in GI bleeding, and incomplete reversal of VKAs/DOACs increases mortality risk.

Non-Critical Major Bleeding

Follow the same algorithm as above but:

• Stop anticoagulant (antiplatelet agents may be continued if bleeding controlled)
• VKA patients: Give 5-10 mg IV vitamin K
• Provide local therapy, supportive care, volume resuscitation
• Assess comorbidities (thrombocytopenia, uremia, liver disease)
• Consider surgical/procedural management 1

Management of Non-Major Bleeding

If Bleeding Controlled with Local Measures

Consider continuing anticoagulant if appropriate indication exists 1

Interventions:

• Local therapy/manual compression (digital compression for epistaxis, tranexamic acid mouthwash for gingival bleeding, compress soaked in tranexamic acid for oral bleeding, oral tranexamic acid for metrorrhagia) 2
• Assess antiplatelet therapy: Evaluate risks/benefits of continuing
• Assess comorbidities contributing to bleeding
• Verify appropriate anticoagulant dosing

If Bleeding Not Immediately Controlled

Stop anticoagulant temporarily 1

Interventions:

• Local therapy/manual compression
• If NOT on VKA: Do not administer reversal agents
• If on VKA: Consider 2-5 mg PO/IV vitamin K (lower dose than major bleeding)
• Supportive care and volume resuscitation
• Stop antiplatelet agents if applicable
• Assess comorbidities

Outpatient management acceptable if:

• Bleeding rapidly controlled
• Medical and social environment permits safe monitoring
• No increased rebleeding risk 2

Essential Diagnostic Evaluation

Obtain immediately:

• Complete blood count with peripheral smear
• Prothrombin time (PT)/INR
• Activated partial thromboplastin time (aPTT)
• Fibrinogen level
• Drug-specific anticoagulant levels when available and patient on DOACs 3

Interpretation patterns:

• Normal PT and aPTT → Platelet disorder
• Normal PT, prolonged aPTT → Intrinsic pathway disorder (hemophilia, von Willebrand disease)
• Prolonged PT, normal aPTT → Extrinsic pathway disorder (vitamin K deficiency, liver disease, warfarin)
• Both prolonged → Common pathway disorder or combined defects 3

Investigate systematically:

• Risk factors for anticoagulant overdose/accumulation: Co-medications, renal insufficiency, contraindications 2
• Bleeding source identification: Imaging, endoscopy, or other modality as indicated
• Family history: Heritable bleeding disorders 3
• Medication history: All anticoagulants, antiplatelets, NSAIDs, herbal supplements

Critical Pitfalls to Avoid

Do not delay definitive hemostatic procedures (surgery, embolization, endoscopy) waiting for reversal agents or laboratory results—proceed immediately while resuscitation continues 2

Do not withhold tranexamic acid in anticoagulated patients when indicated for major bleeding (trauma, post-partum hemorrhage, cardiac surgery)—it acts on different targets than anticoagulants and maintains efficacy 2

Do not forget to plan anticoagulation resumption—delayed or absent resumption increases thromboembolic events after hemorrhage. Once bleeding controlled and source treated, reassess indication and timing for restarting anticoagulation 2

For intracranial hemorrhage or hemorrhagic shock, do not wait for coagulation studies—initiate reversal immediately unless results available within minutes, as point-of-care testing may be utilized 2

Consult hematology when initial evaluation suggests bleeding disorder, when suspicion remains high despite normal laboratory workup, or for rare bleeding disorders 3, 4

Tranexamic Acid Considerations

Administer tranexamic acid according to standard indications regardless of anticoagulant use 2:

• Effective in trauma, cardiac surgery, post-partum hemorrhage
• Reduces epistaxis recurrence at 10 days (including anticoagulated patients)
• Useful for dental procedures in anticoagulated patients
• Not effective in upper GI hemorrhage (HALT-IT study) or non-traumatic intracranial hemorrhage on DOACs (TICH-NOAC study)
• European Stroke Organisation does not recommend for intracranial hemorrhage on VKAs